Status:
COMPLETED
A Study Comparing Infusion Rates of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This 2 arm study will compare the incidence of tocilizumab-related infusion reactions, using 2 different infusion times, in patients with moderate to severe rheumatoid arthritis who have shown an inad...
Eligibility Criteria
Inclusion
- adult patients, \>=18 years of age;
- active moderate or severe rheumatoid arthritis;
- active disease for \>6 months;
- inadequate response to a stable dose of non-biologic DMARDs or antiTNFs.
Exclusion
- rheumatic autoimmune disease other than rheumatoid arthritis;
- prior history of, or current inflammatory joint disease other than rheumatoid arthritis;
- major surgery (including joint surgery) within 8 weeks prior to screening, or planned major surgery within 6 months following enrollment.
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
76 Patients enrolled
Trial Details
Trial ID
NCT00887341
Start Date
May 1 2009
End Date
December 1 2010
Last Update
October 22 2014
Active Locations (24)
Enter a location and click search to find clinical trials sorted by distance.
1
Vitoria-Gasteiz, Alava, Spain, 01009
2
Villajoyosa, Alicante, Spain, 03570
3
Ávila, Avila, Spain, 05071
4
Menorca, Balearic Islands, Spain, 07701